The success of a scientist will depend on their manufacturing of scientific papers and the influence issue of the journal by which they publish. As a result of most main scientific journals are printed in English, success is said to publishing on this language. At present, 98% of publications in science are written in English, together with researchers from English as a International Language (EFL) international locations.
Colombia is among the many international locations with the bottom English proficiency on this planet. Thus, understanding the disadvantages that Colombians face in publishing is essential to decreasing international inequality in science. This paper quantifies the disadvantages that end result from the language hegemony in scientific publishing by analyzing the extra prices that speaking in English creates within the manufacturing of articles.
| anti- Antibody^Polyclonal antibody control antibody | |||
| LSMab09882 | |||
| Lck antibody Antibody | |||
| GWB-250026 | |||
| H2B Antibody Antibody | |||
| E11-184659 | |||
| H2B Antibody Antibody | |||
| MBS8529199-01mg | |||
| H2B Antibody Antibody | |||
| MBS8529199-01mLAF405L | |||
It was recognized that greater than 90% of the scientific articles printed by Colombian researchers are in English, and that publishing in a second language creates extra monetary prices to Colombian doctoral college students and leads to issues with studying comprehension, writing ease and time, and nervousness. Rejection or revision of their articles due to the English grammar was reported by 43.5% of the doctoral college students, and 33% elected to not attend worldwide conferences and conferences because of the necessary use of English in oral shows.
Lastly, among the many translation/enhancing providers reviewed, the fee per article is between one-quarter and one-half of a doctoral month-to-month wage in Colombia. Of specific be aware, we recognized a optimistic correlation between English proficiency and better socioeconomic origin of the researcher. Total, this examine reveals the unfavourable penalties of hegemony of English that preserves the worldwide hole in science.
Though having a standard language is necessary for science communication, producing multilinguistic options would promote variety whereas conserving a communication channel. Such an effort ought to come from totally different actors and mustn’t fall solely on EFL researchers.
| Rat Cholesterol ELISA ELISA | |||
| E01A11128 | |||
| Rat Cholesterol ELISA ELISA | |||
| E02C0745-48wellsplate | |||
| Rat Cholesterol ELISA ELISA | |||
| E02C0745-96wellsplate | |||
Studying Analytics to Assess Beliefs about Science: Evolution of Experience as Seen by way of Organic Inquiry
Epistemological beliefs about science (EBAS) or beliefs in regards to the nature of science information, and the way that information is generated throughout inquiry, are an important but troublesome to evaluate element of science literacy. Leveraging studying analytics to seize and analyze pupil practices in simulated or game-based genuine science actions is a possible avenue for assessing EBAS. Our earlier work characterised inquiry practices of consultants and novices engaged in simulated genuine science inquiry and steered that practices might replicate EBAS.
Right here, we prolong our prior qualitative work to quantitatively study variations in practices and EBAS between non-science majors, biology majors, and biology graduates. We noticed that inquiry practices of non-science majors and biology graduates have been much like the novice and professional practices, respectively, in our prior work.
Nonetheless, biology majors typically appeared to behave like their undergraduate friends (e.g., performing fewer planning actions) however different occasions have been extra much like biology graduates (e.g., performing complicated investigations). We famous that cognitive constructs like metacognition have been additionally necessary for understanding which practices have been most definitely to be reflective of EBAS.
This work advances the right way to assess EBAS utilizing studying analytics and raises questions relating to the event of cognitive processes like EBAS amongst aspiring biologists. The targets of the workshop organized by Piotr Marszalek and Andres Oberhauser that occurred between 29 August and 1 September 2019 at Duke College have been to carry collectively main consultants and junior researchers to overview previous accomplishments, latest advances and limitations within the single-molecule drive spectroscopy subject, which examines nanomechanical forces in numerous organic processes and pathologies. Talks have been organized into 4 periods, and two in-depth roundtable dialogue periods have been held.
| Rat Cholesterol ELISA ELISA | |||
| BlueGene | |||
| Rat Cholesterol ELISA ELISA | |||
| BlueGene | |||
| Rat Cholesterol ELISA ELISA | |||
| BlueGene | |||
Re-thinking the principle targets of organic sciences: is it potential to construct new information with out elementary analysis?
Relationships between collective scientific information and nation’s financial prosperity and competitiveness have been described. Therefore, interactions between business and tutorial establishments is seen as a strategy to valorize this information at social and financial ranges.
The flexibility to translate scientific information in social and financial advantages is now receiving many of the funding for public analysis. Nonetheless, and regardless of the evident long-term advantages of funding utilized science, drastic discount of funds for elementary analysis might ultimately result in the other consequence. This text is protected by copyright. All rights reserved.
| Rat Cholesterol ELISA ELISA | |
| E01A11128 | BlueGene |
| Rat Cholesterol ELISA ELISA | |
| E02C0745-48wellsplate | BlueGene |
| Rat Cholesterol ELISA ELISA | |
| E02C0745-96wellsplate | BlueGene |
| Goat Cholesterol ELISA ELISA | |
| E01A46041 | BlueGene |
| Goat Cholesterol ELISA ELISA | |
| E06C0745-48wellsplate | BlueGene |
Growing old is related to lack of operate throughout organ methods, contributing to systemic frailty. Lack of skeletal muscle mass and performance, particularly, is a serious supply of frailty in older adults, severely impacting high quality of life. Some lack of muscle mass and power with getting old is inevitable, and sarcopenia, the extreme lack of muscle mass with getting old, is frequent. Sarcopenia is decided partially by genetics however may be modified by way of life decisions.
NF-κB reporter (Luc) - HEK293 Cell line |
|||
| 60650 | BPS Bioscience | 2 vials | 1365 EUR |
|
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17. |
|||
NF-kB reporter (Luc) - HEK293 Cell line |
|||
| GWB-PS76F8 | GenWay Biotech | 2X10(6)cells | Ask for price |
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78172-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78172-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78204-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78204-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78205-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78205-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78206-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78206-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78215-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78215-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78614-1 | BPS Bioscience | 100 µl | 860 EUR |
|
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78614-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR |
|
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
Oct4 CR4-pGreenFire Response Reporter (virus) |
|||
| SR20070-VA-1 | SBI | >2 x 10^6 IFUs | 670 EUR |
NF- κB Reporter (Luc) - Raw 264.7 Cell line |
|||
| 79978 | BPS Bioscience | 2 vials | 2045 EUR |
|
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
pGreenZeo lenti reporter |
|||
| PVTY00164 | Nova Lifetech | 2ug | 280 EUR |
NF- κB Reporter (Luc) - THP-1 Cell Line |
|||
| 79645 | BPS Bioscience | 2 vials | 1900 EUR |
|
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
PAI-1 Reporter (Luc) - Mv1 Lu Cell Line |
|||
| 60544 | BPS Bioscience | 2 vials | 3595 EUR |
|
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_ |
|||
Rat NSE Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10024VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
NF-κB reporter (Luc) - NIH/3T3 Cell line |
|||
| 79469 | BPS Bioscience | 2 vials | 1900 EUR |
|
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
Human GFAP Differentiation Reporter (pRedZeo, Virus) |
|||
| SR10051VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
NF-κB Reporter (Luc) - CHO-K1 Cell Line |
|||
| 60622 | BPS Bioscience | 2 vials | 1095 EUR |
|
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling. |
|||
STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin) |
|||
| 79800-P | BPS Bioscience | 2 vials | 3730 EUR |
|
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
Mouse MBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10026VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human LCK Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10032VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1004VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse B29 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1005VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse CD8 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1006VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human CD2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1009VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line |
|||
| 60628 | BPS Bioscience | 2 vials | 7645 EUR |
|
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter. |
|||
Mouse Actc Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10010VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10015VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse GFAP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10016VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10018VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse CD44 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10020VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human BM88 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10021VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Rat Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10034VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse ALBP Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10036VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human NGN3 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10037VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10039VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10040VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human MAP2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10047VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human ACTC Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10049VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human NKX2.5 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10067VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse CD68 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1008VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
NF-κB Reporter (Luc) - A549 Stable Cell Line |
|||
| 60625 | BPS Bioscience | 2 vials | 1915 EUR |
|
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
|||
STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF) |
|||
| 79941 | BPS Bioscience | 2 vials | 1980 EUR |
|
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10012VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10013VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse SM22a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10014VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human CD11b Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10017VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10023VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human Opsin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10027VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human FABP7 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10048VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Rev-A3-GFP/Luc HIV Reporter Cells |
|||
| HRC-3 | 101Bio | 1 vial of 5x10⁶ cells | 1800 EUR |
Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1001VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10022VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human Nestin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10035VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Rev-CEM-GFP/Luc HIV Reporter Cells |
|||
| HRC-5 | 101Bio | 1 vial of 5x10⁶ cells | 1500 EUR |
Human Insulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10028VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human 5-HT1A (Luc) HEK293 Reporter Cell |
|||
| CHEK-ATF131 | ACROBIOSYSTEMS | 2Vials | 14475.2 EUR |
|
Description: This gene encodes a G protein-coupled receptor for 5-hydroxytryptamine (serotonin), and belongs to the 5-hydroxytryptamine receptor subfamily. Serotonin has been implicated in a number of physiologic processes and pathologic conditions. Inactivation of this gene in mice results in behavior consistent with an increased anxiety and stress response. Mutation in the promoter of this gene has been associated with menstrual cycle-dependent periodic fevers. |
|||
Rev-A3R5-GFP/Luc HIV Reporter Cells |
|||
| HRC-2 | 101Bio | 1 vial of 5x10⁶ cells | 1900 EUR |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78028-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78028-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
Lentiviral Dual Reporter: CMV-GFP-T2A-Luciferase pre-packaged virus |
|||
| BLIV101VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Lentiviral Dual Reporter: UBC-RFP-T2A-Luciferase pre-packaged virus |
|||
| BLIV200VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10050VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78348-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
|||
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78348-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
|||
Lentiviral Triple Reporter: CMV-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV102VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Lentiviral Triple Reporter: UBC-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV202VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Lentiviral Triple Reporter: MSCV-Luciferase-RFP-TK pre-packaged virus |
|||
| BLIV302VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1003VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10019VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human SPP-1 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1002VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10011VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
|||
| 60651 | BPS Bioscience | 2 vials | 2340 EUR |
|
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. |
|||
Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro |
|||
| SR10015VA-P | SBI | >2 x 10^6 IFUs | 691 EUR |
Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR1007VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Rev-CEM-Luc HIV Reporter Cells |
|||
| HRC-6 | 101Bio | 1 vial of 5x10⁶ cells | 1500 EUR |
Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10038VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78218-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78218-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility. |
|||
CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line |
|||
| 60626 | BPS Bioscience | 2 vials | 6825 EUR |
|
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_ |
|||
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78112-1 | BPS Bioscience | 100 µl | 875 EUR |
|
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78112-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
|
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
|||
| 79982-1 | BPS Bioscience | 100 µl | 1075 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
|||
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
|||
| 79982-2 | BPS Bioscience | 500 µl x 2 | 8110 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
|||
Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10025VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus) |
|||
| SR10041VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway) |
|||
| 60520 | BPS Bioscience | 2 vials | 2175 EUR |
|
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter. |
|||
GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line |
|||
| 60546 | BPS Bioscience | 2 vials | 10175 EUR |
|
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody. |
|||
Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus |
|||
| SR20071-VA-1 | SBI | >2 x 10^6 IFUs | 670 EUR |
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78142-1 | BPS Bioscience | 100 µl | 860 EUR |
|
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78142-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR |
|
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_ |
|||
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78144-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
|||
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78144-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
|||
Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10070VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway) |
|||
| 79041 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene. |
|||
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78143-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_ |
|||
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78143-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_ |
|||
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78618-1 | BPS Bioscience | 100 µl | 795 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78618-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility. |
|||
Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, virus) |
|||
| SR10068VA-1 | SBI | >2 x 10^6 IFUs | 691 EUR |
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78625-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78625-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78645-1 | BPS Bioscience | 100 µl | 835 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78645-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
BLIV 2.0 Reporter: CMV-Luciferase-EF1a-copGFP Pre-packaged Virus |
|||
| BLIV511VA-1 | SBI | >2 x10^6 IFUs | 722 EUR |
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus), EF1-Neo Marker |
|||
| SR10011VA-N | SBI | >2 x 10^6 IFUs | 691 EUR |
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78651-1 | BPS Bioscience | 100 µl | 875 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Among them, BA.4 and BA.5 have identical mutations on their spike protein. The spike protein of BA.4 and BA.5 are referred as BA.4/5 in this datasheet.The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.4/5 variant in a Biosafety Level 2 facility.As shown in Figures 2 and 3, the Spike Omicron BA.4/5 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.4/5, Omicron Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78651-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. Among them, BA.4 and BA.5 have identical mutations on their spike protein. The spike protein of BA.4 and BA.5 are referred as BA.4/5 in this datasheet.The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.4/5 variant in a Biosafety Level 2 facility.As shown in Figures 2 and 3, the Spike Omicron BA.4/5 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.4/5, Omicron Variant:Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
CRE/CREB Reporter (Luc) - HEK293 Cell Line (cAMP/PKA Signaling Pathway) |
|||
| 60515 | BPS Bioscience | 2 vials | 2070 EUR |
|
Description: The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the cAMP/ PKA signaling pathway. The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into HEK293 cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. |
|||
CRE/CREB Reporter (Luc) - Jurkat Cell Line (cAMP/PKA Signaling Pathway) |
|||
| 79636 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The CRE/CREB Reporter (Luc) - Jurkat Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into Jurkat cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. This cell line is validated for response to stimulation by Forskolin. |
|||
SRE Luciferase Reporter Lentivirus |
|||
| 78627 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The SRE (Serum Response Element) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Serum Response Element located upstream of the minimal TATA promoter . After transduction, activation of the MAPK/ERK signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Myc Luciferase Reporter Lentivirus |
|||
| 78628 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The Myc Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Myc response element located upstream of the minimal TATA promoter and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the Myc signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
p53 Luciferase Reporter Lentivirus |
|||
| 78666 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The p53 Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by p53 response elements located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, p53-regulated gene expression in the target cells can be monitored by measuring the luciferase activity. |
|||
HRE Luciferase Reporter Lentivirus |
|||
| 78668 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The Hypoxia Response Element (HRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of a hypoxia response elements (HRE) located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the induction of hypoxia in the target cells can be monitored by measuring the luciferase activity. |
|||
ARE Luciferase Reporter Lentivirus |
|||
| 79869 | BPS Bioscience | 500 µl x 2 | 875 EUR |
|
Description: The Nrf2 antioxidant response pathway plays an important role in the cellular antioxidant defense. Nrf2, a basic leucine zipper transcription factor, induces the expression of antioxidant and phase II enzymes by binding to the ARE (antioxidant response element) region of the gene promoter. Under basal conditions, Nrf2 is retained in the cytosol by binding to the cytoskeletal protein Keap1. Upon exposure to oxidative stress or other ARE activators, Nrf2 is released from Keap1 and translocates to the nucleus, where it can bind to the ARE, leading to the expression of antioxidant and phase II enzymes that protect the cell from oxidative damage. The ARE Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by ARE located upstream of the minimal TATA promoter. After transduction, activation of the Nrf2 antioxidant response pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway) |
|||
| 60655 | BPS Bioscience | 2 vials | 2275 EUR |
|
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway. |
|||
TEAD Luciferase Reporter Lentivirus |
|||
| 79833 | BPS Bioscience | 500 µl x 2 | 875 EUR |
|
Description: The Hippo pathway regulates cell proliferation and cell death. It is activated by high cell density and cell stress to stop cell proliferation and induce apoptosis. The mammalian Hippo pathway comprises MST kinases and LATS kinases. When the Hippo pathway is activated, MST kinases phosphorylate LATS kinases, which phosphorylate transcriptional co-activators YAP and TAZ. Unphosphorylated YAP and TAZ remain in nucleus and interact with TEAD/TEF transcriptional factors to turn on cell cycle-promoting gene transcription. However, when phosphorylated, YAP and TAZ are recruited from the nucleus to the cytosol, so that the YAP and TAZ-dependent gene transcription is turned off. Dysfunction of the Hippo pathway is frequently detected in human cancer and its down-regulation correlates with the aggressive properties of cancer cells and poor prognosis. The TEAD Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the TEAD response elements located upstream of the minimal TATA promoter. After transduction, activation of the Hippo pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
A549-Dual NFkb-SEAP-IRF-Luc Reporter Cells |
|||
| S0016001 | Addexbio | One Frozen vial | 1400 EUR |
Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78623-1 | BPS Bioscience | 100 µl | 900 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 BA.1 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. A sub-lineage of BA.1 with an R346K substitution in the spike protein is classified as B.1.1.529 BA.1.1.The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 BA.1.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.1.529 BA.1.1 variant in a Biosafety Level 2 facility.The Spike B.1.1.529 BA.1.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in B.1.1.529 BA.1.1 Omicron Variant R346K:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
|||
Spike (BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
| 78623-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
|
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 BA.1 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. A sub-lineage of BA.1 with an R346K substitution in the spike protein is classified as B.1.1.529 BA.1.1.The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 BA.1.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 BA.1.1, Omicron Variant R346K Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.1.529 BA.1.1 variant in a Biosafety Level 2 facility.The Spike B.1.1.529 BA.1.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in B.1.1.529 BA.1.1 Omicron Variant R346K:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
|||
STAT3 Luciferase Reporter Lentivirus |
|||
| 79744 | BPS Bioscience | 500 µl x 2 | 860 EUR |
|
Description: The STAT3 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT3-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT3 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
STAT5 Luciferase Reporter Lentivirus |
|||
| 79745 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The STAT5 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT5-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT5 signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Sox2 SRR2-pGreenFire Response Reporter (pre-packaged virus, EF1-Puro marker) |
|||
| SR20071-VA-P | SBI | >2 x 10^6 IFUs | 670 EUR |
NF-κB Luciferase Reporter Lentivirus |
|||
| 79564 | BPS Bioscience | 500 µl x 2 | 875 EUR |
|
Description: The NF-κB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After transduction, activation of the NF-κB signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
CRE/CREB Luciferase Reporter Lentivirus |
|||
| 79580 | BPS Bioscience | 500 µl x 2 | 835 EUR |
|
Description: The main role of the cAMP response element, or CRE, is mediating the effects of Protein Kinase A (PKA) by way of transcription. Upon phosphorylation, CREB forms a functionally active dimer that binds the CRE element within the promoters of target genes and activates transcription. CRE is at the focus of many extracellular and intracellular signaling pathways, including cAMP, calcium, GPCR (G-protein coupled receptors) and neurotrophins. The cAMP/PKA signaling pathway is critical to numerous life processes in living organisms.The CRE/CREB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized cAMP response element (CRE) located upstream of the minimal TATA promoter. After transduction, activation of the cAMP/PKA signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
pGreenFire 2.0 NFkB reporter virus (pGF2-NFκB-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR412VA-P | SBI | >2 x 10^6 IFUs | 702 EUR |
pGreenFire 2.0 NFAT reporter virus (pGF2-NFAT-rFluc-T2A-GFP-mPGK-Puro) |
|||
| TR451VA-P | SBI | >2 x 10^6 IFUs | 702 EUR |
pGL3 3'UTR reporter WT 1.3 kb CD274 Hs 3'UTR Final Plasmid |
|||
| PVT17094 | Lifescience Market | 2 ug | 390 EUR |
The pathophysiologic underpinnings of sarcopenia are complicated and multifactorial. On this overview, the causes of sarcopenia are surveyed on the methods, cell, subcellular, and molecular ranges with emphasis on the interaction between these numerous causes of this degenerative illness course of. Twenty years in the past, halogen bonding attracted appreciable consideration as a brand new sort of non-covalent interplay and has now emerged as an necessary supramolecular instrument for crystal engineering, demonstrating its means to self-assemble low affinity entities.
| Rat Cholesterol ELISA ELISA | |||
| E01A11128 | |||
| Rat Cholesterol ELISA ELISA | |||
| E02C0745-48wellsplate | |||
| Rat Cholesterol ELISA ELISA | |||
| E02C0745-96wellsplate | |||